Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Andre, Fabrice; O'Regan, Ruth; Ozguroglu, MUSTAFA; Toi, Masakazu; Xu, Binghe; Jerusalem, Guy; Masuda, Norikazu; Wilks, Sharon; Arena, Francis; Isaacs, Claudine; Yap, Yoon-Sim; Papai, Zsuzsanna; Lang, Istvan; Armstrong, Anne; Lerzo, Guillermo; White, Michelle; Shen, Kunwei; Litton, Jennifer; Chen, David; Zhang, Yufen; Ali, Shyanne; Taran, Tetiana; Gianni, Luca

doi:10.1016/s1470-2045(14)70138-x

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Andre F., O'Regan R., Ozguroglu M., Toi M., Xu B., Jerusalem G., ...Daha Fazla

LANCET ONCOLOGY, cilt.15, sa.6, ss.580-591, 2014 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 15 Sayı: 6
Basım Tarihi: 2014
Doi Numarası: 10.1016/s1470-2045(14)70138-x
Dergi Adı: LANCET ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.580-591
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab.